HELICOVAXOR

Development of an oral Helicobacter Pylori vaccine

Coordinatore	SIGMOID PHARMA LIMITED    more  Organization address address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY city: DUBLIN postcode: 9 contact info Titolo: Dr. Nome: Rosa Cognome: Monica Email: send email Telefono: 35317007454
Nazionalità Coordinatore	Ireland [IE]
Totale costo	1˙809˙000 €
EC contributo	1˙303˙000 €
Programma	FP7-SME Specific Programme "Capacities": Research for the benefit of SMEs
Code Call	FP7-SME-2012
Funding Scheme	BSG-SME
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-10-01   -   2014-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	SIGMOID PHARMA LIMITED  Organization address address: THE INVENT CENTRE, DUBLIN CITY UNIVERSITY city: DUBLIN postcode: 9 contact info Titolo: Dr. Nome: Rosa Cognome: Monica Email: send email Telefono: 35317007454	IE (DUBLIN)	coordinator	1˙169˙500.00
2	TELORMEDIX SA  Organization address address: Via della Posta 10 city: Bioggio postcode: 6934 contact info Titolo: Dr. Nome: Alcide Cognome: Barberis Email: send email Telefono: +41 91 610 7000	CH (Bioggio)	participant	108˙500.00
3	GOTOVAX AB  Organization address address: KORVETTGATAN 1D city: VASTRA FROLUNDA postcode: 42674 contact info Titolo: Dr. Nome: Jan Cognome: Holmgren Email: send email Telefono: +46 3 17866200	SE (VASTRA FROLUNDA)	participant	25˙000.00
4	ALLIED AUTOMATION LIMITED  Organization address address: JAMESTOWN ROAD city: DUBLIN postcode: 11 contact info Titolo: Mr. Nome: Dermot Cognome: O'brien Email: send email Telefono: +353 1 834 3905	IE (DUBLIN)	participant	0.00
5	ALMAC DIAGNOSTICS LIMITED  Organization address address: SEAGOE INDUSTRIAL ESTATE 20 city: CRAIGAVON postcode: BT63 5QD contact info Titolo: Dr. Nome: Gareth Cognome: Maguire Email: send email Telefono: +44 28 3833 2200 Fax: +44 2838332299	UK (CRAIGAVON)	participant	0.00
6	CORDEN PHARMA SWITZERLAND LLC  Organization address address: EICHENWEG 1 city: LIESTAL postcode: 4410 contact info Titolo: Mr. Nome: Thomas Cognome: Nsenda Email: send email Telefono: +41 61 906 59 59	CH (LIESTAL)	participant	0.00
7	DIAMOND BIOPHARM LIMITED  Organization address address: "GEMINI HOUSE, EAST WING 4" city: HARLOW postcode: CM19 5TJ contact info Titolo: Mr. Nome: Paul Cognome: Cronin Email: send email Telefono: +44 1 279 441616	UK (HARLOW)	participant	0.00
8	GOETEBORGS UNIVERSITET  Organization address address: VASAPARKEN city: GOETEBORG postcode: 405 30 contact info Titolo: Dr. Nome: Ellen Cognome: Rydberg Email: send email Telefono: +46 31 7866470	SE (GOETEBORG)	participant	0.00
9	MEDITOX S.R.O  Organization address address: POD ZAMKEM 279 city: KONAROVICE postcode: 28125 contact info Titolo: Dr. Nome: Martin Cognome: Slais Email: send email Telefono: +420 313 129 374 5	CZ (KONAROVICE)	participant	0.00
10	PARTICULAR SCIENCES LTD-PSCI  Organization address address: PARK AVENUE 26 CASTLEKNOCK city: DUBLIN postcode: 15 contact info Titolo: Mr. Nome: Sean Cognome: Quilty Email: send email Telefono: +353 1 8205395	IE (DUBLIN)	participant	0.00
11	THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN  Organization address address: College Green - city: DUBLIN postcode: 2 contact info Titolo: Ms. Nome: Deirdre Cognome: Savage Email: send email Telefono: 35318961942 Fax: 35317071633	IE (DUBLIN)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.

Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and only moderate effectiveness. However, with much greater knowledge of the molecular basis of infection and having learnt lessons from previous vaccine developments, the current consortium have drawn together three strand that are considered critical to the development of an effective vaccine: - Powerful, safe and multivalent antigens - Powerful, safe and multi-acting adjuvants - Powerful, modular and flexible oral vaccine delivery system

All three of the above innovative technologies have been proven to be effective in doing what they are required to do, namely:

- Antigens – produce antibodies against a number of key H pylori bacterial components - Adjuvants – stimulate the immune cells to produce significant numbers of long lasting antibodies - Delivery – formulate antigens and adjuvants together and target the stomach and intestine

This consortium (HELICOVAXOR) uniquely converges all three into a true vaccine with real potential to protect from H pylori infection. The vaccine is being designed for oral administration, efficacy, safety and temperature stability.

This consortium has assembled leading academic, industrial and regulatory groups, the activities of which will be coordinated to perform analysis of the formulations, efficacy and safety testing of the vaccines and the preparation of a regulatory dossier, all required before the product can enter human clinical studies.

If successful in pre-clinical studies, the consortium will work with vaccine companies to progress human studies and launch the product as a vaccine to confer protection from H pylori infection.'

Introduzione (Teaser)

A European consortium is developing a novel, orally delivered vaccine against Helicobacter pylori. Using encapsulating technology the vaccine will be administered orally, thereby directly reaching the site of H. pylori infection.